Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityCMCSK / Comcast Corporation (20030N200)
Chairman of Board, Pres. & CEOROBERTS BRIAN L
IndustryCable and Other Pay Television Services
Institutional Owners13
Institutional Shares191,831 - 0.00%
Common Shares Outstanding4,607,671,892 shares (as of 2018-03-31)
Institutional Value$ 6,500,000 USD
Related 00209TAB1 / At&t Broadband Corp 9.455% Notes 11/15/2022
CMCSA / Comcast Corp.
CCV / Comcast Corp., 5.00% Bonds due 12/15/2061
CCV.CL / Comcast Corporation
CCZ / Comcast Holdings Corp., ZONES 2.0% Exchangeable Subor Debentures 11/15/2029

Institutional Stock Ownership and Shareholders()

CMCSK / Comcast Corporation Institutional Ownership

Comcast Corporation (NASDAQ:CMCSK) has 13 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 191,831 shares. Largest shareholders include JP Morgan Chase & Co, JP Morgan Chase & Co, Allianz Asset Management AG, Tourbillon Capital Partners, L.P., Allianz Asset Management AG, SG Americas Securities, LLC, Magnetar Financial LLC, Group One Trading, L.p., Hudson Bay Capital Management LP, and SG Americas Securities, LLC.
Comcast Corporation (NASDAQ:CMCSK) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/cmcsk"><img src="https://images.fintel.io/us-cmcsk-so.png" alt="CMCSK / Comcast Corporation Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-07-09 13F-HR YHB Investment Advisors, Inc. 96,497 125,767 30.33 3,297 4,126 25.14
2018-05-14 13F-HR BOOTHBAY FUND MANAGEMENT, LLC Call 1,000 1,000 0.00 4,005 3,417 -14.68
2018-05-15 13F-HR Tourbillon Capital Partners, L.P. Call 750,000 25,628
2018-07-20 13F-HR WHITTIER TRUST CO 0 5,413 0 289
2018-05-15 13F-HR We Are One Seven, Llc Call 2 0 -100.00 0 0
2018-05-03 13F-HR SG Americas Securities, LLC Put 903,800 427,100 -52.74 528 627 18.75
2018-05-14 13F-HR Hudson Bay Capital Management LP Call 54,100 48,100 -11.09 2,167 1,644 -24.13
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 5,444 3,109 -42.89 258 835 223.64
2018-05-23 13F-HR/A Allianz Asset Management AG Put 5,430,200 1,810,500 -66.66 217,480 61,865 -71.55
2018-05-10 13F-HR Ninepoint Partners Lp 0 60,000 0 2,050
2018-07-20 13F-HR WHITTIER TRUST CO OF NEVADA INC 0 651 0 35
2018-05-10 13F-HR JP Morgan Chase & Co Put 1,754,200 1,945,800 10.92 70,256 66,488 -5.36
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 174,100 131,300 -24.58 6,973 4,487 -35.65
2018-05-11 13F-HR Compagnie Odier SCA Call 16,000 0 -100.00 100 0 -100.00
2018-05-14 13F-HR Hudson Bay Capital Management LP Put 50,000 225,000 350.00 2,003 7,688 283.82
2018-05-11 13F-HR CIBC WORLD MARKETS CORP Put 48,800 0 -100.00 1,954 0 -100.00
2018-05-03 13F-HR SG Americas Securities, LLC Call 531,600 149,400 -71.90 848 68 -91.98
2018-05-02 13F-HR Cooper/haims Advisors, Llc 48 0 -100.00 2 0 -100.00
2018-05-10 13F-HR JP Morgan Chase & Co Call 8,163,100 4,586,600 -43.81 326,932 156,724 -52.06
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 3,732 2,015 -46.01 527 287 -45.54
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 169,400 264,500 56.14 6,784 9,038 33.23
2018-05-15 13F-HR Magnetar Financial LLC Call 0 400,000 0 202
2018-05-23 13F-HR/A Allianz Asset Management AG Call 443,900 481,800 8.54 17,778 16,463 -7.40

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Disney’s big question: How crucial is Sky to its Fox deal?

10h thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com (16-0)

Sky is Comcast’s final prize as Disney battle approaches endgame

19h livemint
London: After raising the white flag in the battle with Walt Disney Co. for the bulk of Rupert Murdoch’s media empire, Comcast Corp. Chief Executive Officer Brian Roberts has one last prize to fight for: the British pay-TV company Sky Plc. (16-0)

Disney prevails in the Fox hunt

2018-07-20 thestar.com.my
Higher bid: Walt Disney Co logo appears on a screen above the floor of the New York Stock Exchange. Thanks to Comcast’s late-stage competing bid that Disney was driven to pay nearly US20bil more than it originally intended to 21st Century Fox Inc. — AP (25-0)

Comcast and Charter Are Selling Their Stakes in the Mets - Bloomberg

2018-07-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (1-0)

Jefferies Makes Huge Media & Entertainment Addition to Franchise Picks List

2018-07-20 247wallst
All the Wall Street firms that we cover here at 24/7 Wall St. keep a list for their institutional and retail clients of high-conviction stock picks. These are generally the companies they not only like on a longer-term basis but those that usually have big upside to the assigned target price. With the summer already half over, many firms on Wall Street have tweaked their lists to account for potential changes the rest of 2018 and beyond, and one company has added an outstanding stock we feel could have outsized upside.

CUSIP: 20030N200